These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 29624033)

  • 1. EFFECT OF DISEASE-MODIFYING ANTIRHEUMATIC DRUGS ON THE VALUES OF APOLIPOPROTEIN A-1 AND ACUTE PHASE REACTANTS IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS.
    Ismaili H; Mulić-Bačić S; Karemani N; Orovčanec N
    Reumatizam; 2016; 63(2):9-14. PubMed ID: 29624033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome of rheumatoid arthritis following adjunct statin therapy.
    Das S; Mohanty M; Padhan P
    Indian J Pharmacol; 2015; 47(6):605-9. PubMed ID: 26729950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of methotrexate and low-dose prednisolone on adiponectine levels and insulin resistance in patients with rheumatoid arthritis naïve to disease-modifying antirheumatic drugs.
    Yaşar Bilge NŞ; Kaşifoğlu N; Kaşifoğlu T; Şahin F; Gönüllü E; Korkmaz C
    Int J Rheum Dis; 2016 Jul; 19(7):665-71. PubMed ID: 26222244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan.
    Matsui T; Kuga Y; Kaneko A; Nishino J; Eto Y; Chiba N; Yasuda M; Saisho K; Shimada K; Tohma S
    Ann Rheum Dis; 2007 Sep; 66(9):1221-6. PubMed ID: 17369281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.
    Smolen JS; Aletaha D
    Arthritis Rheum; 2011 Jan; 63(1):43-52. PubMed ID: 21204103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes of patients with active rheumatoid arthritis with normal acute phase reactant values.
    Chung MK; Park B; Kim IJ; Cho SK; Kim D; Sung YK; Choi CB; Choe JY; Chung WT; Hong SJ; Kim TH; Koh E; Lee SS; Yoon BY; Park H; Bae SC; Lee J
    Int J Rheum Dis; 2019 May; 22(5):852-859. PubMed ID: 30677239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of disease modifying anti-rheumatic drugs on subclinical atherosclerosis and endothelial dysfunction which has been detected in early rheumatoid arthritis: 1-year follow-up study.
    Guin A; Chatterjee Adhikari M; Chakraborty S; Sinhamahapatra P; Ghosh A
    Semin Arthritis Rheum; 2013 Aug; 43(1):48-54. PubMed ID: 23415602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Equivalence of the acute phase reactants C-reactive protein, plasma viscosity, and Westergren erythrocyte sedimentation rate when used to calculate American College of Rheumatology 20% improvement criteria or the Disease Activity Score in patients with early rheumatoid arthritis. Western Consortium of Practicing Rheumatologists.
    Paulus HE; Ramos B; Wong WK; Ahmed A; Bulpitt K; Park G; Sterz M; Clements P
    J Rheumatol; 1999 Nov; 26(11):2324-31. PubMed ID: 10555885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of vitamin D supplementation in improving disease activity in rheumatoid arthritis: An exploratory study.
    Chandrashekara S; Patted A
    Int J Rheum Dis; 2017 Jul; 20(7):825-831. PubMed ID: 26481198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
    Kremer J; Li ZG; Hall S; Fleischmann R; Genovese M; Martin-Mola E; Isaacs JD; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Riese R; Bradley J
    Ann Intern Med; 2013 Aug; 159(4):253-61. PubMed ID: 24026258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Values and Correlations between C-Reactive Protein and Apolipoprotein B after Treatment with Methotrexate at Patients with Rheumatoid Arthritis.
    Ismaili H; Ismaili L; Rexhepi M
    Open Access Maced J Med Sci; 2019 Apr; 7(8):1293-1298. PubMed ID: 31110572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab.
    Nordal HH; Brun JG; Hordvik M; Eidsheim M; Jonsson R; Halse AK
    Scand J Rheumatol; 2016 Jul; 45(4):274-81. PubMed ID: 26767827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined measurement of multiple acute phase reactants to predict relapse of rheumatoid arthritis.
    Lv F; Song LJ; Li XF
    Int J Rheum Dis; 2015 Sep; 18(7):725-30. PubMed ID: 24131533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The comparative responsiveness of the patient self-report questionnaires and composite disease indices for assessing rheumatoid arthritis activity in routine care.
    Salaffi F; Ciapetti A; Gasparini S; Carotti M; Bombardieri S;
    Clin Exp Rheumatol; 2012; 30(6):912-21. PubMed ID: 22935335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
    Genovese MC; McKay JD; Nasonov EL; Mysler EF; da Silva NA; Alecock E; Woodworth T; Gomez-Reino JJ
    Arthritis Rheum; 2008 Oct; 58(10):2968-80. PubMed ID: 18821691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Disease-modifying treatment for inflammatory rheumatism in sub-Saharan Africa: outcome at 6 months of 205 Senegalese patients with rheumatoid arthritis].
    Ndongo S; Pouye A; Lekpa FK; Bihéhé DM; Tiendrebeogo J; Ndao AC; Ka MM; Moreira Diop T
    Med Sante Trop; 2012; 22(4):385-9. PubMed ID: 23352953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis.
    Liao KP; Playford MP; Frits M; Coblyn JS; Iannaccone C; Weinblatt ME; Shadick NS; Mehta NN
    J Am Heart Assoc; 2015 Jan; 4(2):. PubMed ID: 25637346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of patients with rheumatoid arthritis in Qatar: a cross-sectional study.
    Lutf A; Poil AR; Hammoudeh M
    Int J Rheum Dis; 2014 Jan; 17(1):63-5. PubMed ID: 24472269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use.
    Proudman SM; James MJ; Spargo LD; Metcalf RG; Sullivan TR; Rischmueller M; Flabouris K; Wechalekar MD; Lee AT; Cleland LG
    Ann Rheum Dis; 2015 Jan; 74(1):89-95. PubMed ID: 24081439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating cell free DNA: a marker to predict the therapeutic response for biological DMARDs in rheumatoid arthritis.
    Hashimoto T; Yoshida K; Hashimoto N; Nakai A; Kaneshiro K; Suzuki K; Kawasaki Y; Shibanuma N; Hashiramoto A
    Int J Rheum Dis; 2017 Jun; 20(6):722-730. PubMed ID: 27943573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.